Showing results (3991-4000 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|July 22, 2020
Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric CancerThomas Benjamin Karasic, Mark H O'Hara, Ursina R Teitelbaum, et al.
The Oncologist|January 25, 2014
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinomaJifang Gong, Bing Hu, Xiaotian Zhang, et al.
The Oncologist|June 15, 2014
6-thioguanine: a drug with unrealized potential for cancer therapyPashna N Munshi, Martin Lubin, Joseph R Bertino
The Oncologist|June 6, 2014
The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failureAmy E DeZern, Mikkael A Sekeres
The Oncologist|June 22, 2014
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxomaFilippo Pietrantonio, Claudia Maggi, Giuseppe Fanetti, et al.
The Oncologist|June 22, 2014
Quality of life in the trastuzumab for gastric cancer trialTaroh Satoh, Yung-Jue Bang, Evgeny A Gotovkin, et al.
The Oncologist|February 7, 2015
The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trialsYoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, et al.
The Oncologist|February 7, 2015
External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancerVéronique Tack, Marjolijn J L Ligtenberg, Lien Tembuyser, et al.
The Oncologist|March 18, 2015
Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinomaArpit Rao, Richard Lauer
The Oncologist|March 22, 2015
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumorsChooi Peng Lee, N Jane Taylor, Gerhardt Attard, et al.
Pageof 571